Female-led stocks: Who rules the world?
34 No. of Symbols
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
40.75 MXN
68.60 B MXN
835.91 B MXN
2.01 B
About GSK plc
Sector
Industry
CEO
Emma N. Walmsley
Website
Headquarters
London
ISIN
US37733W2044
FIGI
BBG00JX0NSM0
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS29462437
GlaxoSmithKline Capital Plc 5.25% 10-APR-2042Yield to maturity
5.97%
Maturity date
Apr 10, 2042
17RI
GlaxoSmithKline Capital Plc 4.25% 18-DEC-2045Yield to maturity
5.61%
Maturity date
Dec 18, 2045
71ZC
GlaxoSmithKline Capital Plc 6.375% 09-MAR-2039Yield to maturity
5.61%
Maturity date
Mar 9, 2039
XS217060907
GlaxoSmithKline Capital Plc 1.625% 12-MAY-2035Yield to maturity
5.28%
Maturity date
May 12, 2035
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043Yield to maturity
5.20%
Maturity date
Mar 18, 2043
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038Yield to maturity
4.97%
Maturity date
May 15, 2038
XS14051686
GlaxoSmithKline Capital Plc 5.25% 19-DEC-2033Yield to maturity
4.87%
Maturity date
Dec 19, 2033
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035Yield to maturity
4.67%
Maturity date
Apr 15, 2035
72WI
GlaxoSmithKline Capital, Inc. 5.375% 15-APR-2034Yield to maturity
4.66%
Maturity date
Apr 15, 2034
XS217060184
GlaxoSmithKline Capital Plc 1.25% 12-OCT-2028Yield to maturity
4.15%
Maturity date
Oct 12, 2028
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030Yield to maturity
4.13%
Maturity date
Apr 15, 2030
See all GSK/N bonds
Curated watchlists where GSK/N is featured.
Frequently Asked Questions
The current price of GSK/N is 715.00 MXN — it has increased by 0.85% in the past 24 hours. Watch GSK plc Sponsored ADR stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange GSK plc Sponsored ADR stocks are traded under the ticker GSK/N.
GSK/N stock is 2.83% volatile and has beta coefficient of 0.33. Track GSK plc Sponsored ADR stock price on the chart and check out the list of the most volatile stocks — is GSK plc Sponsored ADR there?
Today GSK plc Sponsored ADR has the market capitalization of 1.50 T, it has increased by 4.82% over the last week.
Yes, you can track GSK plc Sponsored ADR financials in yearly and quarterly reports right on TradingView.
GSK plc Sponsored ADR is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
GSK/N earnings for the last quarter are 23.19 MXN per share, whereas the estimation was 21.96 MXN resulting in a 5.58% surprise. The estimated earnings for the next quarter are 22.77 MXN per share. See more details about GSK plc Sponsored ADR earnings.
GSK plc Sponsored ADR revenue for the last quarter amounts to 199.10 B MXN, despite the estimated figure of 196.90 B MXN. In the next quarter, revenue is expected to reach 200.41 B MXN.
GSK/N net income for the last quarter is 36.16 B MXN, while the quarter before that showed 41.90 B MXN of net income which accounts for −13.71% change. Track more GSK plc Sponsored ADR financial stats to get the full picture.
Yes, GSK/N dividends are paid quarterly. The last dividend per share was 7.89 MXN. As of today, Dividend Yield (TTM)% is 3.98%. Tracking GSK plc Sponsored ADR dividends might help you take more informed decisions.
GSK plc Sponsored ADR dividend yield was 4.53% in 2024, and payout ratio reached 94.89%. The year before the numbers were 3.87% and 47.48% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 22, 2025, the company has 68.63 K employees. See our rating of the largest employees — is GSK plc Sponsored ADR on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK plc Sponsored ADR EBITDA is 223.94 B MXN, and current EBITDA margin is 26.18%. See more stats in GSK plc Sponsored ADR financial statements.
Like other stocks, GSK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK plc Sponsored ADR stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK plc Sponsored ADR technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK plc Sponsored ADR stock shows the sell signal. See more of GSK plc Sponsored ADR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.